



YejM Modulates Activity of the YciM/FtsH Protease Complex To Prevent Lethal Accumulation of Lipopolysaccharide

Randi L. Guest,^a Daniel Samé Guerra,^a Maria Wissler,^a Jacqueline Grimm,^a Thomas J. Silhavy^a

^aDepartment of Molecular Biology, Princeton University, Lewis Thomas Laboratory, Princeton, New Jersey, USA

ABSTRACT Lipopolysaccharide (LPS) is an essential glycolipid present in the outer membrane (OM) of many Gram-negative bacteria. Balanced biosynthesis of LPS is critical for cell viability; too little LPS weakens the OM, while too much LPS is lethal. In *Escherichia coli*, this balance is maintained by the YciM/FtsH protease complex, which adjusts LPS levels by degrading the LPS biosynthesis enzyme LpxC. Here, we provide evidence that activity of the YciM/FtsH protease complex is inhibited by the essential protein YejM. Using strains in which LpxC activity is reduced, we show that *yciM* is epistatic to *yejM*, demonstrating that YejM acts upstream of YciM to prevent toxic overproduction of LPS. Previous studies have shown that this toxicity can be suppressed by deleting *lpp*, which codes for a highly abundant OM lipoprotein. It was assumed that deletion of *lpp* restores lipid balance by increasing the number of acyl chains available for glycerophospholipid biosynthesis. We show that this is not the case. Rather, our data suggest that preventing attachment of *lpp* to the peptidoglycan sacculus allows excess LPS to be shed in vesicles. We propose that this loss of OM material allows continued transport of LPS to the OM, thus preventing lethal accumulation of LPS within the inner membrane. Overall, our data justify the commitment of three essential inner membrane proteins to avoid toxic over- or underproduction of LPS.

IMPORTANCE Gram-negative bacteria are encapsulated by an outer membrane (OM) that is impermeable to large and hydrophobic molecules. As such, these bacteria are intrinsically resistant to several clinically relevant antibiotics. To better understand how the OM is established or maintained, we sought to clarify the function of the essential protein YejM in *Escherichia coli*. Here, we show that YejM inhibits activity of the YciM/FtsH protease complex, which regulates synthesis of the essential OM glycolipid lipopolysaccharide (LPS). Our data suggest that disrupting proper communication between LPS synthesis and transport to the OM leads to accumulation of LPS within the inner membrane (IM). The lethality associated with this event can be suppressed by increasing OM vesiculation. Our research has identified a completely novel signaling pathway that we propose coordinates LPS synthesis and transport.

KEYWORDS lipopolysaccharide, proteolysis, LpxC, FtsH, YciM, YejM, outer membrane

Nearly all bacteria are surrounded by a multilayered envelope that separates the cytoplasm from the external environment (1). In both Gram-positive and Gram-negative bacteria, this envelope consists of a cytoplasmic/inner membrane (IM) and the peptidoglycan sacculus. Gram-negative bacteria contain an additional layer called the outer membrane (OM), which lies on the external face of the peptidoglycan. The OM is an asymmetric lipid bilayer with the glycolipid lipopolysaccharide (LPS) in the outer leaflet and glycerophospholipids (PLs) in the inner leaflet (2). This membrane forms a robust permeability barrier that substantially slows the influx of large and hydrophobic molecules and works together with the peptidoglycan to provide mechanical strength to the cell (3). Both functions arise from the strong lateral interactions between neighboring molecules of LPS, which are densely packed within the outer leaflet.

Citation Guest RL, Samé Guerra D, Wissler M, Grimm J, Silhavy TJ. 2020. YejM modulates activity of the YciM/FtsH protease complex to prevent lethal accumulation of lipopolysaccharide. mBio 11:e00598-20. <https://doi.org/10.1128/mBio.00598-20>.

Editor Susan Gottesman, National Cancer Institute

Copyright © 2020 Guest et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Thomas J. Silhavy, tsilhavy@princeton.edu.

This article is a direct contribution from Thomas J. Silhavy, a Fellow of the American Academy of Microbiology, who arranged for and secured reviews by M. Stephen Trent, University of Georgia; Mario Feldman, Washington University School of Medicine; and Alessandra Polissi, University of Milan.

Received 12 March 2020

Accepted 16 March 2020

Published 14 April 2020

The basic structure of LPS consists of the glucosamine-based phospholipid lipid A connected to a core oligosaccharide (lipid A-core) (4). Additional polysaccharides can be attached to lipid A-core, including O antigen, enterobacterial common antigen, and colanic acid (5–7). Notably, laboratory strains of *Escherichia coli* K-12 do not synthesize O antigen, and modification of LPS with enterobacterial common antigen or colonic acid is rare under normal growth conditions (6–8). As such, the majority of LPS in *E. coli* K-12 is in the form of lipid A-core. Synthesis of lipid A-core occurs on the cytoplasmic face of the IM (4). In *E. coli*, the first step in lipid A biosynthesis is catalyzed by LpxA, which attaches a single acyl chain to UDP-GlcNAc (UDP-*N*-acetylglucosamine) to form UDP-monoacyl-GlcNAc (9). UDP-monoacyl-GlcNAc is then deacetylated by LpxC (10), which makes room for a second acyl chain to be added. The reaction catalyzed by LpxA has an unfavorable equilibrium constant, and as such, LpxC performs the first committed step of lipid A biosynthesis (10, 11). The amount of LpxC is regulated by the protease FtsH (12). Delivery of LpxC to FtsH is mediated by the adaptor protein YciM (13), an integral IM protein with a cytoplasmic region containing nine tetratricopeptide repeat (TPR) motifs and a rubredoxin-like domain (14–16). Null mutations in either *ftsH* or *yciM* are lethal due to increased LPS biosynthesis (13, 16), which is thought to deplete the cell of acyl chains that are needed for PL biosynthesis (12). Mutations that rebalance the ratio of LPS to PLs by either lowering LPS or increasing PL biosynthesis suppress deletion of *ftsH* or *yciM* (12, 13). It has previously been shown that deletion of the highly abundant lipoprotein Lpp, which tethers the OM to the underlying peptidoglycan, can suppress deletion of *yciM* (13, 16–18). As Lpp is anchored to the OM by three acyl chains (19), it has been hypothesized that loss of *lpp* restores lipid balance in the Δ *yciM* mutant by increasing the number of acyl chains available for PL biosynthesis (16, 20).

YejM is an essential IM protein containing a nonessential C-terminal globular domain that extends into the periplasmic space between the inner and outer membranes (21–23). The membrane and globular domains are connected by a basic linker region that is required for YejM function but is not essential for viability. *E. coli* lacking the globular domain and linker region of YejM displays several phenotypes that are characteristic of OM barrier defects, including sensitivity to large and hydrophobic antibiotics, impaired growth at elevated temperatures, and leakage of periplasmic proteins (24, 25). It has also been reported that *yejM* mutants have a lower ratio of LPS to PLs, suggesting that loss of YejM activity may alter OM lipid synthesis (24, 25). More recent studies suggest that YejM transports cardiolipin to the OM (23). However, this does not explain why *yejM* is essential, since *E. coli* can survive without cardiolipin (26). Moreover, the OM defects caused by truncation of YejM persist in the absence of cardiolipin (27). As such, the essential function performed by YejM that impacts OM integrity remains completely unknown.

In this study, we show that YejM acts upstream of YciM to restrain degradation of LpxC by FtsH. We also show that simply preventing attachment of Lpp to the peptidoglycan by a mutation that does not impact protein expression or acylation prevents the lethality caused by unrestrained synthesis of LPS. We propose that this lethality occurs because of LPS in the IM. Loss of OM material due to hypervesiculation in the *lpp* mutants allows LPS transport to keep up with this unrestrained synthesis, preventing toxic accumulation within the IM. Overall, our data suggest that the essential function of YejM is to control activity of the YciM/FtsH protease complex.

RESULTS

Mutations in *yciM* and *lpxC* suppress the OM defect of the *yejM569* mutant. To clarify the function of YejM, we screened for suppressors of the OM permeability and temperature sensitivity phenotypes of *E. coli* expressing *yejM569*, a truncated version of YejM lacking its globular and linker domains. It has previously been shown that the temperature sensitivity of *E. coli* expressing the truncated YejM can be restored by expressing a wild-type copy of *yejM* in *trans*, suggesting that removing the globular and linker domains reduces YejM activity (21). Cells expressing *yejM569* were incubated under nonpermissive conditions (42°C or SDS/EDTA) until suppressor colonies grew. We




FIG 1 Mutations in *yciM* and *lpxC* suppress the outer membrane (OM) defect of the *yejM569* mutant. Serial dilutions of the indicated strains were spotted onto LB or LB supplemented with 0.5% SDS and 0.5 mM EDTA. Bacteria spotted on LB were grown at 30°C or 42°C while those spotted on LB containing SDS and EDTA were grown at 30°C. (A) *yciM_{A143E}*, *yciM_{A376P}*, and *yciM_{390Q}* rescue growth of the *yejM569::cam* mutant under nonpermissive conditions. All strains contain the *yciM::Tn10* allele, which is genetically linked to *yciM*. The strains shown are RLG431, RLG467, RLG507, RLG509, and RLG511. (B) *lpxC_{R230L}* and *lpxC^{*306fs}* allow *E. coli* containing the *yejM569::cam* allele to grow under nonpermissive conditions. All strains contain the *leuB::Tn10* allele, which is linked to *lpxC*. The strains shown are RLG433, RLG547, RLG548, and RLG550. Data are representative of three independent experiments. WT, wild type; *, stop codon; fs, frameshift.

identified several mutations in *yciM* and *lpxC* that suppress both the OM permeability defect and the temperature sensitivity of *yejM569* (Fig. 1). One suppressor in YciM exchanged an alanine for glutamic acid at residue 143 in TPR four, while another contains an alanine-to-proline substitution at residue 376 in the rubredoxin-like domain. Mutation of the stop codon in YciM to glutamine, which extends the protein by eight amino acids, also suppresses the OM defect of the *yejM569* mutant (Fig. 1A). One mutation in LpxC that suppress *yejM569* exchanges a conserved arginine for a leucine at residue 230. LpxC^{*306fs} contains a frameshift mutation that removes two nucleotides in the stop codon and extends the protein by 20 amino acids. Given that both YciM and LpxC are involved in lipid A biosynthesis (10, 13), our data suggest that the OM defect caused by loss of the periplasmic domain of YejM can be corrected by modulating the level of LPS.

LPS levels are reduced in the truncated *yejM* mutant. While our data suggest that altering LPS biosynthesis suppresses the OM defect of the *yejM569* mutant, it was not clear whether the suppressors increase or decrease LPS levels. To investigate this, we determined whether a gain-of-function mutation in *yciM* (*yciM_{V43G}*) that decreases levels of both LpxC and LPS (28, 29) can suppress *yejM569*. We were unable to introduce the *yejM569* allele into *E. coli* expressing *yciM_{V43G}*, suggesting that these mutations may be synthetically lethal. To test this hypothesis, we introduced *yejM569* into a *yciM_{V43G}* mutant expressing a wild-type copy of *yejM* from an arabinose-inducible promoter. In the presence of arabinose, the *yejM569 yciM_{V43G}* double mutant is viable (Fig. 2A). However, when expression of wild-type *yejM* is repressed by adding fucose to the growth medium, the *yejM569 yciM_{V43G}* double mutant fails to grow (Fig. 2A). Depletion of *yejM* with fucose did not impair growth of the *yciM_{V43G}* single mutant, which encodes a wild-type copy of *yejM* at the native locus, or the *yejM569* single mutant (Fig. 2A). These results demonstrate that *yejM569* and *yciM_{V43G}* are synthetically lethal and suggest that lowering LPS levels in the *yejM569* mutant is toxic.

To confirm that decreased LPS levels prevent growth of the *yejM569* mutant, we determined whether *yejM569* is synthetically lethal with *lpxC101*, an allele of *lpxC* that decreases lipid A biosynthesis (10, 30, 31). *yejM569* was introduced into a *lpxC101*




FIG 2 *yejM569* lowers lipopolysaccharide (LPS) levels and mutations that suppress *yejM569* increase LPS. (A and B) Tenfold serial dilutions of the indicated strains containing a plasmid expressing wild-type (WT) *yejM* from an arabinose-inducible promoter were grown on LB containing 0.2% arabinose or 0.05% fucose at 30°C. (A) The *yciM_{V43G} yejM569* double mutant fails to grow unless a wild-type copy of *yejM* is expressed. All strains contain the *ycjM::Tn10* marker. (B) The *lpxC101 yejM569* double mutant cannot grow unless wild-type *yejM* is expressed. (C and D) LPS levels were determined by immunoblot analysis using antibodies that recognize LPS. Antibodies recognizing RpoA were used as a loading control. LPS levels in the *yejM569* mutant are decreased. Relative quantification indicates LPS levels compared to the levels in the wild type. (C) Suppressor mutations in *yciM* increase LPS levels in the *yejM569* mutant. All strains contain *ycjM::Tn10*. (D) Suppressor mutations in *lpxC* increase LPS in the *yejM569* mutant. All strains contain the *leuB::Tn10* allele. Data are representative of three independent experiments. *, stop codon; fs, frameshift.

mutant expressing a wild-type copy of *yejM* from an arabinose-inducible promoter, and the ability of this strain to grow in the presence of arabinose or fucose was assessed. Much like the *yciM_{V43G}* mutant, the *yejM569 lpxC101* double mutant could not grow when *yejM569* was the sole copy expressed (Fig. 2B). These data provide additional evidence to suggest that the *yejM569* mutant fails to grow when LPS levels are decreased. As such, it is likely that mutations in *yciM* and *lpxC* that suppress the OM defect caused by truncation of YejM act to increase LPS.

Our data suggest that the *yejM569* mutation alone may lower LPS levels, and when paired with additional mutations that also lower LPS, the combined decrease cannot support growth. To quantify levels of LPS, we utilized immunoblot analysis with an antibody raised against LPS. We observed an approximate twofold decrease in LPS levels in the *yejM569* mutant compared to that of the wild type (Fig. 2C and D). Mutations in *yciM* and *lpxC* that suppress the OM defect of the *yejM569* mutant increase LPS levels in this background to different extents. LPS levels in the *yejM569 yciM_{A376P}* double mutant were higher than that of the *yejM569* single mutant but lower than that of the wild type (Fig. 2C). LPS levels in all other suppressors were higher than in both the *yejM569* single mutant and wild type. Compared to the wild type, LPS levels in the *yejM569* mutants expressing *yciM_{A143E}*, *yciM_{S390Q}*, and *lpxC_{S309fs}* were increased by 2.04-, 1.25-, and 2.97-fold, respectively (Fig. 2C and D). The *yejM569 lpxC_{R230L}* mutant had the highest level of LPS, which was nearly fourfold higher than that of the wild type (Fig. 2D). Taken together, these data




FIG 3 *yciM* is epistatic to *yejM569*. Serially diluted strains were plated on LB supplemented with 0.2% arabinose or 0.05% fucose. All strains contain the *yciM*::Tn10 marker and a plasmid encoding a wild-type copy of *yejM* from an arabinose-inducible promoter. Deletion of *yciM* rescues the synthetic lethality of the *yejM569 lpxC101* double mutant, suggesting that *yejM* functions upstream of *yciM* to regulate LPS. Data are representative of three biological replicates.

suggest that loss of the periplasmic domain in YejM lowers LPS levels and that the OM defect in this mutant can be corrected by increasing LPS.

The LpxC degradation pathway is activated in the *yejM569* mutant. We next wanted to determine how *yejM569* lowers LPS levels. Clues as to how this may occur come from the mutations that suppress the OM defect of the *yejM569* mutant. *yciM*_{A143E}, *yciM*_{A376P}, and *yciM*_{390Q} increase LPS levels in the *yejM569* strain, suggesting that these mutations likely stabilize LpxC by impairing activity of YciM. Furthermore, the *lpxC*_{306fs} mutation extends the carboxy terminus of LpxC, which has previously been shown to block degradation by FtsH (32). As such, *yejM569* may reduce LPS levels by increasing degradation of LpxC by the YciM/FtsH protease complex. To test this hypothesis, we took advantage of the synthetic lethality between *yejM569* and *lpxC101*. If the *yejM569 lpxC101* double mutant fails to grow because degradation of LpxC101 is increased, then preventing LpxC101 degradation by deleting *yciM* would restore viability. Alternatively, if *yejM569* lowers LPS independently of the YciM/FtsH protease complex, then the *yejM569 lpxC101* double mutant would fail to grow even in the absence of *yciM*. *yciM* was deleted in the *yejM569 lpxC101* double mutant expressing a wild-type copy of *yejM* from an arabinose-inducible promoter. Notably, *yciM* is not essential in the *lpxC101* background as LPS levels are decreased (13) (Fig. 3). As we observed previously (Fig. 2B), the *yejM569 lpxC101* double mutant does not grow when wild-type *yejM* is depleted (Fig. 3). However, the *yejM569 lpxC101 ΔyciM* triple mutant is viable when only *yejM569* is expressed (Fig. 3). These data are consistent with the hypothesis that *yejM569* lowers LPS levels by increasing activity of the YciM/FtsH protease complex.

YejM is not essential when the YciM/FtsH protease complex is inactivated. Our data suggest that truncation of YejM stimulates degradation of LpxC by the YciM/FtsH protease complex. As such, we hypothesized that loss of the entire YejM protein is lethal because the YciM/FtsH protease complex is hyperactivated. To test this hypothesis, we determined whether *yejM* is essential in *E. coli* lacking *yciM*. As *yciM* is also essential, we suppressed deletion of *yciM* by lowering the level of LPS with the *lpxC101* mutation. The chromosomal copy of *yejM* was deleted in wild-type *E. coli*, as well as the *lpxC101* single mutant and the $\Delta yciM$ *lpxC101* double mutant each expressing a wild-type copy of *yejM* from an arabinose-inducible promoter. Growth of the YejM depletion strain is arabinose dependent (Fig. 4A), confirming that *yejM* is essential. The *lpxC101* mutation did not rescue growth of the YejM depletion strain on fucose (Fig. 4A), demonstrating that lowering LPS levels does not suppress deletion of *yejM*. However, depletion of YejM is tolerated in the $\Delta yciM$ *lpxC101* double mutant (Fig. 4A), suggesting that the *yejM* is not essential in *E. coli* lacking *yciM*.

To ensure that suppressing depletion of YejM is due to deletion of *yciM* and is not specific to the $\Delta yciM$ *lpxC101* double mutant, we examined whether YejM can be depleted in a $\Delta yciM$ mutant that has been suppressed through a different mechanism. Previous studies have shown that deletion of *yciM* is tolerated in *E. coli* lacking *lpp* (13, 16). It is thought that deletion of *lpp* restores OM lipid balance in the *yciM* mutant by increasing the number of acyl chains available for PL biosynthesis (16, 20). As seen in




FIG 4 *yejM* is not essential in *E. coli* lacking *yciM*. Wild-type *E. coli* or *E. coli* containing the indicated mutations were serially diluted and plated on LB containing 0.2% arabinose or 0.05% fucose. All strains express a wild-type copy of *yejM* from an arabinose-inducible promoter on a plasmid. Deletion of *yciM* was suppressed with *lppC101* (A) or by deleting *lpp* (B). Data are representative of three biological replicates.

Fig. 4B, deletion of *lpp* does not suppress depletion of YejM. However, YejM can be depleted in the $\Delta yciM$ Δlpp double mutant (Fig. 4B), confirming that *yejM* is not essential when *yciM* is absent. Together, these results demonstrate that the essential function performed by YejM is dependent on YciM and suggest that loss of *yejM* may hyperactivate the YciM/FtsH protease complex.

Mutations in *lpp* suppress loss of YciM by lowering LPS. Previous studies have proposed that elevated LPS biosynthesis resulting from deletion of *ftsH* or *yciM* is lethal due to reduced availability of acyl chains required for PL biosynthesis (12, 16, 33). To investigate whether deletion of *lpp* suppresses deletion of *yciM* by liberating acyl chains normally sequestered by this abundant lipoprotein (16, 20), we determined whether deletion of *yciM* is tolerated in *E. coli* lacking the C-terminal lysine residue that attaches Lpp to the peptidoglycan sacculus (34). Unhooking Lpp from the peptidoglycan leads to many of the same phenotypes as deleting *lpp* entirely (17). However, mutating the K58 residue does not affect Lpp expression or localization to the OM (35), suggesting that Lpp^{ΔK58} is lipidated and would sequester acyl chains like the wild type. We compared growth of a $\Delta yciM$ Δlpp double mutant containing a plasmid expressing wild-type *lpp* or *lpp*_{ΔK58} from an arabinose-inducible promoter to that of a $\Delta yciM$ Δlpp mutant containing an empty vector. When grown in the presence of arabinose, the $\Delta yciM$ mutant that does not carry *lpp* grew better than the $\Delta yciM$ mutant expressing wild-type *lpp* (Fig. 5A), confirming that loss of *lpp* suppresses deletion of *yciM*. The period of exponential growth in the $\Delta yciM$ mutant expressing wild-type *lpp* likely represents the time required to establish a strong covalent linkage between the OM and the peptidoglycan upon inducing *lpp* expression. Growth of the $\Delta yciM$ mutant expressing *lpp*_{ΔK58} was similar to that of the $\Delta yciM$ mutant that does not bear *lpp* (Fig. 5A), suggesting that loss of *lpp* does not suppress deletion of *yciM* by liberating acyl chains for lipid biosynthesis.

Unhooking Lpp from the peptidoglycan disrupts OM integrity, promotes OM vesiculation, and prevents proper communication across the periplasm by increasing the distance between the inner and outer membranes (17). To narrow down which of these phenotypes is responsible for suppressing deletion of *yciM*, we monitored growth of the $\Delta yciM$ Δlpp mutant expressing a plasmid-borne, arabinose-inducible copy of *lpp*₊₁₄, a mutation that extends the length of Lpp by 14 amino acids (36). Both Lpp^{ΔK58} and Lpp₊₁₄ increase the length of the periplasm by an average of 3 nm; however, Lpp₊₁₄




FIG 5 Mutations in *lpp* suppress deletion of *yciM* by decreasing levels of LPS. (A and B) Growth of the *ΔyciM Δlpp* double mutant (A) and the *Δlpp* single mutant harboring plasmid pBAD18 or pBAD18 expressing wild-type *lpp*, *lpp*_{ΔK58}, *lpp*₊₁₄, or *lpp*₊₂₁ from an arabinose-inducible promoter (B). Bacteria were diluted into LB supplemented with 0.5% arabinose. OD₆₀₀ which was used as a proxy for growth, was measured every 15 min for 12 h. Data represent the means and standard deviations of three biological replicates. (C) Immunoblot analysis of LPS levels in the *ΔyciM Δlpp* double mutant containing pBAD18 or pBAD18 expressing wild-type *lpp* or *lpp*_{ΔK58} from an arabinose-inducible promoter. RecA was used as a loading control. (D) Immunoblot analysis of LpxC levels in the *ΔyciM Δlpp* double mutant containing pBAD18 or pBAD18 expressing wild-type *lpp* or *lpp*_{ΔK58} from an arabinose-inducible promoter. As LpxC levels are increased in the *ΔyciM* mutant (13, 16), the band corresponding to LpxC was identified by comparing *ΔyciM Δlpp* double mutants and a *Δlpp* single mutant expressing wild-type *lpp* from an arabinose-inducible promoter. This band was confirmed to be LpxC using the *lpxC101* mutation, which significantly increases LpxC levels (29). The presence of a nonspecific band is indicated by an asterisk. (E) OM vesicles in the wild type, the *Δlpp* and *lpxC101* single mutants, and the *Δlpp ΔyciM* and *lpxC101 ΔyciM* double mutants. RpoA was used as a cytoplasmic marker, while OmpC/F/A and LPS were used as markers of the OM. Increased amounts of OmpC/F/A and LPS in the OM vesicle fraction indicate that the *Δlpp* and *Δlpp ΔyciM* mutants hypervesiculate. Data in panels C to E are representative of two or more independent experiments. Lanes in panels C to E: —, vector; WT, wild type; WCL, whole-cell lysate; OMV, outer membrane vesicles.

does not affect OM permeability or vesiculation (36). The $\Delta yciM$ mutant expressing lpp_{+14} grows better than that expressing wild-type lpp , but worse than the $\Delta yciM$ mutant lacking lpp entirely (Fig. 5A). Further increasing the distance between the inner and outer membranes by extending the length of Lpp by 21 amino acids (36, 37) leads to better growth than when lpp_{+14} is expressed (Fig. 5A). However, the $\Delta yciM$ mutant expressing lpp_{+21} still does not grow as well as the $\Delta yciM$ mutant lacking lpp (Fig. 5A). Expression of lpp_{+14} and lpp_{+21} is not toxic in cells expressing a wild-type copy of $yciM$ (Fig. 5B), indicating that impaired growth of the $\Delta yciM$ mutants expressing lpp_{+14} and lpp_{+21} is specifically due to the loss of $yciM$. Given that lpp_{+14} and lpp_{+21} do not suppress deletion of $yciM$ to the same extent as deletion of lpp or $lpp_{\Delta K58}$, it is unlikely that loss of lpp suppresses deletion of $yciM$ by increasing the distance between the inner and outer membrane.

As many of the mutations that suppress deletion of $yciM$ are known to affect LPS levels (13, 16), we hypothesized that mutating lpp may alter LPS levels in *E. coli* lacking $yciM$. In support of this hypothesis, deletion of lpp has been shown to suppress the lethality associated with hyperactivation of the OM phospholipase PldA by decreasing LPS levels (28). We found that the $\Delta yciM$ mutants that lacked lpp or expressed $lpp_{\Delta K58}$ had approximately 2.5-fold-less LPS than the $\Delta yciM$ mutant expressing wild-type lpp (Fig. 5C). These data suggest that loss of Lpp function suppresses deletion of $yciM$ by decreasing levels of LPS. To determine whether loss of Lpp in the $\Delta yciM$ mutant affects LPS biosynthesis, we measured levels of LpxC. We found that the level of LpxC in the $\Delta yciM$ mutant lacking lpp or expressing $lpp_{\Delta K58}$ is similar to that expressing wild-type lpp (Fig. 5D), suggesting that loss of Lpp or unhooking Lpp from the peptidoglycan may reduce LPS levels without affecting LPS biosynthesis. Instead, it is likely that loss of Lpp function lowers LPS by increasing OM vesiculation. To test this hypothesis, we quantified OM vesicles in wild-type *E. coli*, the Δlpp single mutant, and the $\Delta lpp \Delta yciM$ double mutant. We found that OM vesicles are produced in both the Δlpp and $\Delta lpp \Delta yciM$ mutants and that OM vesicles from the $\Delta lpp \Delta yciM$ mutant have increased LPS (Fig. 5E). OM vesicles are not detected in the $\Delta yciM lpxC101$ mutant (Fig. 5E), suggesting that production of OM vesicles is specific to the $\Delta lpp \Delta yciM$ double mutant.

DISCUSSION

In this study, we sought to better understand the role of the essential protein YejM in OM biogenesis. Our data suggest that removing the nonessential globular and linker domains of YejM, which reduces YejM activity (21), lowers LPS levels in a $yciM$ -dependent manner. Consequently, these cells are sensitive to detergents and cannot grow at elevated temperatures. As YciM is the adaptor protein that delivers LpxC to FtsH for degradation (13), it is likely that partial loss of YejM activity lowers LPS levels by increasing proteolysis of LpxC. These data suggest that complete loss of $yejM$ is lethal because the YciM/FtsH protease complex is hyperactivated. Indeed, we found that $yejM$ is no longer essential in *E. coli* lacking $yciM$. Overall, our findings indicate that YejM inhibits the YciM/FtsH protease complex, which is responsible for degrading LpxC. OM defects associated with truncation of YejM in *Salmonella enterica* serovar Typhimurium can also be suppressed by mutations in $yciM$, $lpxC$, and $ftsH$ (38), suggesting that control of LpxC degradation may be a conserved function of YejM.

Several studies have shown that LpxC degradation is regulated by fatty acids. Lipid A and PLs use the same fatty acids, suggesting that competition must exist between these two biosynthetic pathways for precursors. As such, previous studies hypothesized that LpxC degradation is regulated to ensure that sufficient fatty acids are available for PL biosynthesis (12, 33). In support of this model, increased activity of the fatty acid biosynthesis enzyme FabZ stabilizes LpxC (12, 39). However, overexpression of other genes involved in fatty acid biosynthesis have the opposite effect on LpxC stability (39, 40). As such, it is unclear whether LpxC is regulated in order to balance biosynthesis of PLs and LPS (40). Aberrant accumulation of PLs in the outer leaflet of the OM, which denotes a greater need for LPS, also stabilizes LpxC (29). Fatty acids released upon breakdown of outer leaflet PLs by the phospholipase PldA are imported into the

cytoplasm, where they inhibit activity of the YciM/FtsH protease complex. A recent study has shown that PldA is protective in *E. coli* lacking part of the YejM globular domain (27), suggesting that PldA activity may stabilize LpxC in the *yejM* mutant. LpxC stability is correlated with levels of the alarmone guanosine tetraphosphate (ppGpp) (41). LpxC is rapidly degraded during slow growth, when ppGpp levels are high. In contrast, during fast growth when ppGpp levels are low, LpxC is stabilized. This regulatory pattern is reversed when ppGpp is eliminated. Most recently, it was shown that LpxC is degraded upon overexpression of PyrH, an essential protein involved in pyrimidine biosynthesis (39). It is thought that PyrH overexpression may change levels of UDP-GlcNAc, a precursor for lipid A biosynthesis.

How these diverse signals are sensed by YciM and/or FtsH is not clear. Many of these signals affect production of lipid A disaccharide, an intermediate of lipid A biosynthesis (40). Computational modeling suggests that accumulation of lipid A disaccharide stimulates degradation of LpxC, a finding supported by experimental data (40). Whether YejM is required for lipid A disaccharide to regulate LpxC degradation is unknown. Previous studies have shown that the periplasmic domain of YejM is able to bind lipids (22, 23). However, it is unlikely that these regions of YejM are able to interact with lipid A disaccharide, which is located on the cytoplasmic side of the IM. Further studies are needed to test whether lipid A disaccharide is a key biosynthetic intermediate, and if so, how its levels are detected and integrated into the YejM and YciM/FtsH regulatory circuit.

Deleting *yciM* stabilizes LpxC, which leads to constitutive biosynthesis of LPS (13, 16). This lethal event can be suppressed by deleting *lpp*, which codes for a highly abundant lipoprotein that tethers the OM to the underlying peptidoglycan sacculus (13, 16–18). Here, we show that deletion of *yciM* is tolerated in *E. coli* producing a mutant version of Lpp (Lpp^{ΔK58}) that cannot attach to the peptidoglycan (34). Given that Lpp^{ΔK58} is lipidated, these data challenge the notion that loss of Lpp suppresses deletion of *yciM* by increasing the number of acyl chains available for PL biosynthesis. Rather, our data suggest that suppression is due to greatly weakened anchoring of the OM to the peptidoglycan. It is well-known that Δlpp and $lpp_{\Delta K58}$ mutants increase production of OM vesicles (36, 37, 42–44), and our data suggest that the $\Delta yciM \Delta lpp$ double mutant produces OM vesicles. We propose that these vesicles help the cell to shed the excess LPS produced because of *yciM* deletion. In support of this hypothesis, OM vesicles produced in strains synthesizing larger amounts of LPS are enriched with lipids (44). Although we cannot exclude the possibility that deletion of *lpp* reduces LPS levels by affecting LPS biosynthesis at a step downstream of LpxC, we do not think this likely. A previous study has found that deletion of *yciM* is tolerated in *E. coli* lacking other proteins that attach the OM to the peptidoglycan, including Pal and OmpA (13). Furthermore, production of OM vesicles increases in *E. coli* with moderately increased levels of LPS (44), suggesting that OM vesiculation may be an adaptive response to increased LPS biosynthesis. As such, we favor the hypothesis that deletion of *lpp* lowers LPS levels by increasing OM vesiculation.

It has been proposed that transport of LPS from the IM to the OM is inhibited once a critical level of LPS within the OM is reached (45). Accordingly, it is likely that the excess LPS produced in the $\Delta yciM$ mutant accumulates in the IM once transport to the OM has stopped. Indeed, *E. coli* lacking FtsH has been shown to accumulate membranous material within the periplasm, a large portion of which is likely LPS (12). In the Δlpp mutant, it is possible that transport is not inhibited because excess LPS is lost in OM vesicles. As a result, LPS accumulation within the IM would be minimized. For these reasons, we propose that it is accumulated LPS within the IM of the $\Delta yciM$ mutant that causes lethality and that deletion of *lpp* reduces lethality by increasing transport of LPS to the OM.

It stands to reason that IM LPS may be sensed by the cell, which would respond by decreasing LPS synthesis. In support of this hypothesis, it has been shown that depletion of proteins involved in LPS transport to the OM increases expression of FtsH and lowers levels of LPS (29, 46). We propose that YejM is at the center of this regulatory




FIG 6 YejM alters activity of the YciM/FtsH protease complex to prevent lipopolysaccharide (LPS) accumulation in the inner membrane (IM). (A) Under normal conditions, YejM inhibits activity of the YciM/FtsH protease complex. LpxC is stabilized, which promotes LPS biosynthesis. LPS is transported to the outer membrane (OM) by the LPS transport pathway. (B) Accumulation of LPS in the outer leaflet of the IM inhibits activity of YejM. Activity of the YciM/FtsH protease complex is derepressed, leading to increased degradation of LpxC. Lower levels of LpxC reduce biosynthesis of LPS.

pathway. Under normal conditions, YejM acts to inhibit activity of YciM, which stabilizes LpxC, allowing for lipid A biosynthesis to occur (Fig. 6A). However, if LPS biosynthesis begins to outpace transport to the OM, LPS accumulates within the IM. Under these conditions, inhibition of YciM by YejM is relieved, which restores homeostasis by reducing lipid A biosynthesis (Fig. 6B). How YejM senses this event remains to be determined. Given that YejM can bind lipids (22, 23), it is possible that changes in the lipid environment of the IM upon accumulation of LPS regulate activity of YejM. This regulation would happen without the need for additional protein synthesis, allowing the cell to rapidly sense and respond to LPS that has accumulated within the IM.

Our study demonstrates that the levels of LpxC must be tightly regulated. A partial decrease in LpxC leads to defects in OM integrity and complete destruction is lethal. However, an unrestrained increase in LpxC is also lethal due to aberrant accumulation of LPS within the IM. The overall importance of this proteolytic regulatory circuit for LpxC is evidenced by the fact that three essential IM proteins, YejM, YciM, and FtsH, have been assigned to carefully balance LPS synthesis in order to maintain the OM barrier during cell growth even in rapidly changing environments.

MATERIALS AND METHODS

Bacterial growth conditions. Unless otherwise stated, bacteria were cultured in Lennox broth (LB) or LB agar at 30°C. LB was supplemented with ampicillin (Amp) (125 $\mu\text{g ml}^{-1}$), chloramphenicol (Cam) (20 $\mu\text{g ml}^{-1}$), kanamycin (Kan) (25 $\mu\text{g ml}^{-1}$), tetracycline (Tet) (10 $\mu\text{g ml}^{-1}$), L-arabinose (0.2% [wt/vol] or 0.5% [wt/vol]), D-fucose (0.05% [wt/vol]), isopropyl- β -D-thiogalactopyranoside (IPTG, 2.5 μM), sodium dodecyl sulfate (SDS, 0.5% [wt/vol]), and/or EDTA (0.5 mM), as necessary.

Strain construction. All bacterial strains and plasmids used in this study are listed in Table S1 in the supplemental material, and all oligonucleotides are listed in Table S2. Unless otherwise stated, chromosomal mutations were introduced into *E. coli* strains MG1655 and JCM158 using generalized transduction (47). Alleles of *yciM* and *lpxC* were moved into *E. coli* JCM158 using the genetically linked markers *ycjM::Tn10* and *leuB::Tn10*, respectively, with the exception of the Δ *yciM::kan* null allele, which was selected for directly. To remove the *leuB::Tn10* marker from *E. coli* expressing the *lpxC101* allele, cells were transduced with P1vir raised in wild-type *E. coli* and selected for on M63 minimal medium agar supplemented with 0.4% glucose, 1 mM MgSO_4 , and 125 $\mu\text{g ml}^{-1}$ thiamine. Point mutations were confirmed by DNA sequencing, and null mutations were confirmed by PCR.

Null alleles of *yciM* and *lpp* were obtained from the Keio library (48). The kanamycin resistance cassette in the Δ *lpp::kan* Keio allele was removed by flippase/flippase recognition target (FLP/FRT) site-specific recombination generally as described in reference 49. pCP20, which expresses FLP from a temperature-sensitive promoter, was transformed into *E. coli* containing the Keio allele. Transformants were recovered in LB at 30°C for 1 h and selected for on LB agar supplemented with chloramphenicol at 30°C. The following day, single colonies were grown in LB at 37°C for 6 h to induce FLP expression and to prevent pCP20 from replicating. Serial dilutions were plated on LB medium and grown overnight at 37°C. To confirm that the bacteria had lost pCP20, colonies were screened for chloramphenicol sensitivity. The kanamycin resistance cassette in the Δ *yciM::kan* Keio allele was removed by FLP/FRT recombination as described in reference 50 with all steps performed at 30°C or room temperature. Loss of the

kanamycin resistance cassette was confirmed by screening for kanamycin sensitivity and PCR. The scar region following FLP/FRT recombination contains a single FRT site (51).

Both the *yejM569::cam* and *ΔyejM::kan* alleles were constructed by λ Red recombination as previously described (52). To generate the *yejM569::cam* allele, the chloramphenicol resistance cassette and FRT sites were amplified from the plasmid pKD3 (51) using primers *yejM*Frecomb and *yejM*Rrecomb. The *yejM569::cam* DNA was purified and transformed into strain DY378, which encodes the λ Red recombination system from a temperature-sensitive promoter. Recombinants were selected for on LB containing chloramphenicol, and the presence of the *yejM569::cam* allele was confirmed by PCR. To generate the *ΔyejM::kan* allele, the kanamycin resistance cassette and flanking FRT sites were amplified from the Keio library (48) using primers *yejM*Kan.Fwd and *yejM*Kan.Rev. Purified *ΔyejM::kan* DNA was transformed into strain RLG429, a derivative of DY378 that expresses a wild-type copy of *yejM* from an IPTG-inducible promoter on plasmid pCA-*yejM*. Recombinants were selected for on LB agar supplemented with kanamycin, chloramphenicol, and IPTG. The presence of the *ΔyejM::kan* allele was confirmed by PCR.

Plasmid construction. To construct the plasmid pBAD18-*yejM*, wild-type *yejM* was amplified from the chromosome of strain JCM158 using the oligonucleotides *yejM*KpnI.Fwd and *yejM*HindIII.Rev. Both the purified PCR product and pBAD18 were digested with KpnI (NEB) and HindIII (NEB) according to the manufacturer's recommendations. The digested *yejM* DNA was then ligated into the digested pBAD18 vector using T4 DNA ligase (NEB) in the supplied buffer at room temperature for 1 h. Ligated plasmid was transformed into Mach1 chemically competent *E. coli* (Invitrogen) according to the manufacturer's protocol. Transformants were selected for on LB agar supplemented with ampicillin. PCR and DNA sequencing were used to confirm successful cloning of *yejM* into pBAD18.

pBAD18-*lpp*₊₁₄ was constructed using Q5 site-directed mutagenesis (NEB). pBAD18-*lpp* was amplified with the oligonucleotides *lpp*14.Fwd and *lpp*14.Rev. The resulting PCR product was digested with DpnI overnight at 37°C in order to remove the template DNA. The following day, the 5' ends of the linear pBAD18-*lpp*₊₁₄ DNA were phosphorylated using T4 polynucleotide kinase (NEB), and the DNA was circularized using T4 DNA ligase (NEB). Ligated plasmid DNA was transformed into Mach1 chemically competent *E. coli* (Invitrogen) according to the manufacturer's protocol, and transformants were selected for on LB agar supplemented with ampicillin at 37°C. The resulting *lpp*₊₁₄ allele contains a TLSAKVEQL SNDVN insertion between *Lpp*^{D42} and *Lpp*^{Q43}, which extends the length of *Lpp* by 14 amino acids (36). The pBAD18-*lpp*₊₂₁ plasmid was constructed using a similar procedure; however, pBAD18-*lpp* was instead amplified with the primers *lpp*21.Fwd and *lpp*21.Rev. *Lpp*₊₂₁ contains a TLSAKVEQLSNDVNAM RSDVD insertion between residues D42 and Q43 and extends the protein by 21 amino acids (36). Mutagenesis of pBAD18-*lpp*₊₁₄ and pBAD18-*lpp*₊₂₁ was confirmed by DNA sequencing.

Isolation and identification of suppressor mutations. Overnight cultures of *E. coli* expressing *yejM569* were plated on LB agar at 42°C or LB agar containing 0.5% SDS and 0.5 mM EDTA at 30°C and incubated until colonies formed. Suppressor mutations in LpxC were identified by whole-genome sequencing. Genomic DNA of the parent strain and the suppressors was isolated using the DNeasy blood and tissue kit (Qiagen) following the manufacturer's protocol for isolation of DNA from Gram-negative bacteria. An Illumina (CA) sequencing library of the DNA was prepared using the Nextera DNA library prep kit and was sequenced using an Illumina HiSeq 2500 sequencer. Whole-genome sequencing and analysis were performed by the Princeton University Lewis-Sigler Institute Genomics Core Facility. Mutations in *yciM* were identified by Sanger sequencing (Genewiz) using the primers *yciM*_F and *yciM*_R.

Efficiency of plating. Bacterial cultures grown overnight were standardized by optical density at 600 nm (OD₆₀₀) and then serially diluted by a factor of 10 in a 96-well plate. Bacteria were transferred to the indicated agar medium using a 96-well plate replica plater and grown overnight at 30°C unless otherwise stated.

Immunoblot analysis. For experiments with *E. coli* expressing *yejM569*, bacteria were grown to an OD₆₀₀ of 0.4 to 0.6 in 5 ml LB at 30°C in a roller drum. Three milliliters of culture was collected, and bacteria were pelleted by centrifugation at 21,130 × *g* for 1 min at room temperature. The supernatant was removed, and bacteria were flash frozen in liquid nitrogen. Frozen pellets were resuspended in lysis buffer (25 mM Tris [pH 6.8] with 1% SDS) and boiled for 5 min. The protein concentration of each sample was measured using the Pierce BCA protein assay kit (ThermoFisher). Samples were standardized by protein concentration, diluted twofold in sample buffer (125 mM Tris [pH 6.8], 2.5% glycerol, 3% SDS, 0.5 mg/ml bromophenol blue, 4% β -mercaptoethanol), and electrophoresed on a 10% SDS-polyacrylamide gel. To look at LPS levels in the *ΔyciM* mutants, bacteria were grown overnight in 200 μ l LB containing Amp and 0.5% L-arabinose in a 96-well plate at 30°C as described below for growth curves. Bacteria were concentrated to an OD₆₀₀ of 1.25 in sample buffer and lysed by boiling for 5 min. Samples were electrophoresed on a 10% or 12% SDS-polyacrylamide gel. LPS and proteins were transferred to a nitrocellulose membrane using the Trans-Blot Turbo Transfer System (Bio-Rad). Primary antibodies detecting LPS core (Hycult Biotech), LpxC, OmpC/F/A, RecA, and RpoA were used at a 1:5,000, 1:10,000, 1:30,000, 1:10,000, and 1:50,000 dilution, respectively. Goat anti-mouse horseradish peroxidase (HRP) conjugate (Bio-Rad) and goat anti-rabbit peroxidase (Sigma-Aldrich) secondary antibodies were each used at a 1:10,000 dilution.

Growth curve. Overnight cultures of bacteria grown in 5 ml LB supplemented with Amp and D-fucose were diluted to an OD₆₀₀ of approximately 0.02 in 2 ml LB supplemented with Amp and 0.5% L-arabinose. Two hundred microliters of each culture was transferred to each well on a 96-well plate, which was then covered with a Breathe-Easy gas-permeable membrane (Sigma-Aldrich). Bacteria were grown overnight in the Synergy H1 microplate reader (BioTek) at 30°C with shaking. OD₆₀₀ was measured every 15 min for 12 h.

Fractionation of OM vesicles. OM vesicles were collected as described in reference 29. Bacteria were grown for 16 h in 5 ml LB at 30°C. Bacteria equivalent to an OD₆₀₀ of 1 were pelleted by centrifugation at 21,130 × *g* for 1 min at room temperature and resuspended in 100 μl of sample buffer and lysed by boiling for 5 min. Bacteria in the remainder of the culture were pelleted by centrifugation at approximately 3,500 rpm for 10 min at 4°C. The supernatant was then filtered through a 0.2-μm filter. Supernatant equivalent to an OD₆₀₀ of 3 was collected, and the volume was equalized between samples with fresh LB. The supernatants were then filtered through an Amicon Ultra-15 centrifugal filter unit (Millipore) with a molecular weight cutoff of 100 kDa. Samples were resuspended in 50 μl and boiled for 5 min. Proteins were separated by electrophoresis on a 10% SDS-polyacrylamide gel and detected via immunoblot analysis.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

TABLE S1, DOCX file, 0.03 MB.

TABLE S2, DOCX file, 0.02 MB.

ACKNOWLEDGMENTS

We thank members of the Silhavy laboratory for helpful discussions and critically reading the manuscript. We also thank Kelly Hughes for his insightful comments. Thank you to Wei Wang and Jessica Wiggins at the Lewis-Sigler Institute Genomics Core Facility of Princeton University for performing the whole-genome sequencing and analyzing the data. We are grateful to Herbert Schweizer for the pFLP2 plasmid, John Cronan for strain MW06, and Franz Narberhaus for the LpxC antibody.

This research was supported by the National Institute of General Medical Sciences of the National Institutes of Health under grants 5R35GM118024 (to T.J.S.) and T32-GM007388 (to Princeton University – J.G.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This research was conceptualized by R.L.G., J.G., and T.J.S. R.L.G., D.S.G., M.W., and J.G. performed the research. R.L.G., D.S.G., J.G., and T.J.S. wrote the paper.

REFERENCES

- Silhavy TJ, Kahne D, Walker S. 2010. The bacterial cell envelope. *Cold Spring Harb Perspect Biol* 2:a000414. <https://doi.org/10.1101/cshperspect.a000414>.
- Smit J, Kamio Y, Nikaido H. 1975. Outer membrane of *Salmonella typhimurium*: chemical analysis and freeze-fracture studies with lipopolysaccharide mutants. *J Bacteriol* 124:942–958. <https://doi.org/10.1128/JB.124.2.942-958.1975>.
- Rojas ER, Billings G, Odermatt PD, Auer GK, Zhu L, Miguel A, Chang F, Weibel DB, Theriot JA, Huang KC. 2018. The outer membrane is an essential load-bearing element in Gram-negative bacteria. *Nature* 559:617–621. <https://doi.org/10.1038/s41586-018-0344-3>.
- Whitfield C, Trent MS. 2014. Biosynthesis and export of bacterial lipopolysaccharides. *Annu Rev Biochem* 83:99–128. <https://doi.org/10.1146/annurev-biochem-060713-035600>.
- Schmidt G, Mannel D, Mayer H, Whang HY, Neter E. 1976. Role of a lipopolysaccharide gene for immunogenicity of the enterobacterial common antigen. *J Bacteriol* 126:579–586. <https://doi.org/10.1128/JB.126.2.579-586.1976>.
- Meredith TC, Mamat U, Kaczynski Z, Lindner B, Holst O, Woodard RW. 2007. Modification of lipopolysaccharide with colanic acid (M-antigen) repeats in *Escherichia coli*. *J Biol Chem* 282:7790–7798. <https://doi.org/10.1074/jbc.M611034200>.
- Kuhn HM, Meier-Dieter U, Mayer H. 1988. ECA, the enterobacterial common antigen. *FEMS Microbiol Rev* 4:195–222. <https://doi.org/10.1111/j.1574-6968.1988.tb02743.x>.
- Liu D, Reeves PR. 1994. *Escherichia coli* K12 regains its O antigen. *Microbiology* 140:49–57. <https://doi.org/10.1099/13500872-140-1-49>.
- Anderson MS, Raetz CR. 1987. Biosynthesis of lipid A precursors in *Escherichia coli*. A cytoplasmic acyltransferase that converts UDP-N-acetylglucosamine to UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine. *J Biol Chem* 262:5159–5169.
- Young K, Silver LL, Bramhill D, Cameron P, Eveland SS, Raetz CR, Hyland SA, Anderson MS. 1995. The *envA* permeability/cell division gene of *Escherichia coli* encodes the second enzyme of lipid A biosynthesis. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase. *J Biol Chem* 270:30384–30391. <https://doi.org/10.1074/jbc.270.51.30384>.
- Anderson MS, Bull HG, Galloway SM, Kelly TM, Mohan S, Radika K, Raetz CR. 1993. UDP-N-acetylglucosamine acyltransferase of *Escherichia coli*. The first step of endotoxin biosynthesis is thermodynamically unfavorable. *J Biol Chem* 268:19858–19865.
- Ogura T, Inoue K, Tatsuta T, Suzuki T, Karata K, Young K, Su LH, Fierke CA, Jackman JE, Raetz CR, Coleman J, Tomoyasu T, Matsuzawa H. 1999. Balanced biosynthesis of major membrane components through regulated degradation of the committed enzyme of lipid A biosynthesis by the AAA protease FtsH (HflB) in *Escherichia coli*. *Mol Microbiol* 31:833–844. <https://doi.org/10.1046/j.1365-2958.1999.01221.x>.
- Mahalakshmi S, Sunayana MR, SaiSree L, Reddy M. 2014. *yciM* is an essential gene required for regulation of lipopolysaccharide synthesis in *Escherichia coli*. *Mol Microbiol* 91:145–157. <https://doi.org/10.1111/mmi.12452>.
- Nicolaes V, El Hajjaji H, Davis RM, Van der Henst C, Depuydt M, Leverrier P, Aertsen A, Haufroid V, Ollagnier-de Choudens S, De Bolle X, Ruiz N, Collet J-F. 2014. Insights into the function of *YciM*, a heat shock membrane protein required to maintain envelope integrity in *Escherichia coli*. *J Bacteriol* 196:300–309. <https://doi.org/10.1128/JB.00921-13>.
- Prince C, Jia Z. 2015. An unexpected duo: rubredoxin binds nine TPR motifs to form LapB, an essential regulator of lipopolysaccharide synthesis. *Structure* 23:1500–1506. <https://doi.org/10.1016/j.str.2015.06.011>.
- Klein G, Kobylak N, Lindner B, Stupak A, Raina S. 2014. Assembly of lipopolysaccharide in *Escherichia coli* requires the essential LapB heat shock protein. *J Biol Chem* 289:14829–14853. <https://doi.org/10.1074/jbc.M113.539494>.
- Asmar AT, Collet J-F. 2018. Lpp, the Braun lipoprotein, turns 50—major achievements and remaining issues. *FEMS Microbiol Lett* 365:fny199. <https://doi.org/10.1093/femsle/fny199>.

18. Yu F, Furukawa H, Nakamura K, Mizushima S. 1984. Mechanism of localization of major outer membrane lipoprotein in *Escherichia coli*. Studies with the OmpF-lipoprotein hybrid protein. *J Biol Chem* 259: 6013–6018.
19. Hantke K, Braun V. 1973. Covalent binding of lipid to protein. Diglyceride and amide-linked fatty acid at the N-terminal end of the murein-lipoprotein of the *Escherichia coli* outer membrane. *Eur J Biochem* 34:284–296. <https://doi.org/10.1111/j.1432-1033.1973.tb02757.x>.
20. Klein G, Raina S. 2019. Regulated assembly of LPS, its structural alterations and cellular response to LPS defects. *Int J Mol Sci* 20:356. <https://doi.org/10.3390/ijms20020356>.
21. De Lay NR, Cronan JE. 2008. Genetic interaction between the *Escherichia coli* AcpT phosphopantetheinyl transferase and the YejM inner membrane protein. *Genetics* 178:1327–1337. <https://doi.org/10.1534/genetics.107.081836>.
22. Dong H, Zhang Z, Tang X, Huang S, Li H, Peng B, Dong C. 2016. Structural insights into cardiolipin transfer from the inner membrane to the outer membrane by PbgA in Gram-negative bacteria. *Sci Rep* 6:30815. <https://doi.org/10.1038/srep30815>.
23. Dalebroux ZD, Edrozo MB, Pfuetzner RA, Ressler S, Kulasekara BR, Blanc M-P, Miller SI. 2015. Delivery of cardiolipins to the *Salmonella* outer membrane is necessary for survival within host tissues and virulence. *Cell Host Microbe* 17:441–451. <https://doi.org/10.1016/j.chom.2015.03.003>.
24. Hirvas L, Nurminen M, Helander IM, Vuorio R, Vaara M. 1997. The lipid A biosynthesis deficiency of the *Escherichia coli* antibiotic-supersensitive mutant LH530 is suppressed by a novel locus, ORF195. *Microbiology* 143:73–81. <https://doi.org/10.1099/00221287-143-1-73>.
25. Nurminen M, Hirvas L, Vaara M. 1997. The outer membrane of lipid A-deficient *Escherichia coli* mutant LH530 has reduced levels of OmpF and leaks periplasmic enzymes. *Microbiology* 143:1533–1537. <https://doi.org/10.1099/00221287-143-5-1533>.
26. Tan BK, Bogdanov M, Zhao J, Dowhan W, Raetz CRH, Guan Z. 2012. Discovery of a cardiolipin synthase utilizing phosphatidylethanolamine and phosphatidylglycerol as substrates. *Proc Natl Acad Sci U S A* 109: 16504–16509. <https://doi.org/10.1073/pnas.1212797109>.
27. Qiu N, Misra R. 2019. Overcoming iron deficiency of an *Escherichia coli* tonB mutant by increasing outer membrane permeability. *J Bacteriol* 201:e00340-19. <https://doi.org/10.1128/JB.00340-19>.
28. Sutterlin HA, Shi H, May KL, Miguel A, Khare S, Huang KC, Silhavy TJ. 2016. Disruption of lipid homeostasis in the Gram-negative cell envelope activates a novel cell death pathway. *Proc Natl Acad Sci U S A* 113: E1565–E1574. <https://doi.org/10.1073/pnas.1601375113>.
29. May KL, Silhavy TJ. 2018. The *Escherichia coli* phospholipase PldA regulates outer membrane homeostasis via lipid signaling. *mBio* 9:e00379-18. <https://doi.org/10.1128/mBio.00379-18>.
30. Beall B, Lutkenhaus J. 1987. Sequence analysis, transcriptional organization, and insertional mutagenesis of the envA gene of *Escherichia coli*. *J Bacteriol* 169:5408–5415. <https://doi.org/10.1128/jb.169.12.5408-5415.1987>.
31. Jackman JE, Raetz CR, Fierke CA. 2001. Site-directed mutagenesis of the bacterial metalloamidase UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC). Identification of the zinc binding site. *Biochemistry* 40: 514–523. <https://doi.org/10.1021/bi001872g>.
32. Führer F, Langklotz S, Narberhaus F. 2006. The C-terminal end of LpxC is required for degradation by the FtsH protease. *Mol Microbiol* 59: 1025–1036. <https://doi.org/10.1111/j.1365-2958.2005.04994.x>.
33. Zeng D, Zhao J, Chung HS, Guan Z, Raetz CRH, Zhou P. 2013. Mutants resistant to LpxC inhibitors by rebalancing cellular homeostasis. *J Biol Chem* 288:5475–5486. <https://doi.org/10.1074/jbc.M112.447607>.
34. Zhang WY, Wu HC. 1992. Alterations of the carboxyl-terminal amino acid residues of *Escherichia coli* lipoprotein affect the formation of murein-bound lipoprotein. *J Biol Chem* 267:19560–19564.
35. Yakushi T, Tajima T, Matsuyama S, Tokuda H. 1997. Lethality of the covalent linkage between mislocalized major outer membrane lipoprotein and the peptidoglycan of *Escherichia coli*. *J Bacteriol* 179: 2857–2862. <https://doi.org/10.1128/jb.179.9.2857-2862.1997>.
36. Asmar AT, Ferreira JL, Cohen EJ, Cho S-H, Beeby M, Hughes KT, Collet J-F. 2017. Communication across the bacterial cell envelope depends on the size of the periplasm. *PLoS Biol* 15:e2004303. <https://doi.org/10.1371/journal.pbio.2004303>.
37. Cohen EJ, Ferreira JL, Ladinsky MS, Beeby M, Hughes KT. 2017. Nanoscale-length control of the flagellar driveshaft requires hitting the tethered outer membrane. *Science* 356:197–200. <https://doi.org/10.1126/science.aam6512>.
38. Cian MB, Giordano NP, Masilamani R, Minor KE, Dalebroux ZD. 2019. *Salmonella enterica* serovar Typhimurium uses PbgA/YejM to regulate lipopolysaccharide assembly during bacteremia. *Infect Immun* 88: e00758-19. <https://doi.org/10.1128/IAI.00758-19>.
39. Thomanek N, Arends J, Lindemann C, Barkovits K, Meyer HE, Marcus K, Narberhaus F. 2018. Intricate crosstalk between lipopolysaccharide, phospholipid and fatty acid metabolism in *Escherichia coli* modulates proteolysis of LpxC. *Front Microbiol* 9:3285. <https://doi.org/10.3389/fmicb.2018.03285>.
40. Emiola A, Andrews SS, Heller C, George J. 2016. Crosstalk between the lipopolysaccharide and phospholipid pathways during outer membrane biogenesis in *Escherichia coli*. *Proc Natl Acad Sci U S A* 113:3108–3113. <https://doi.org/10.1073/pnas.1521168113>.
41. Schäkermann M, Langklotz S, Narberhaus F. 2013. FtsH-mediated coordination of lipopolysaccharide biosynthesis in *Escherichia coli* correlates with the growth rate and the alarmone (p)ppGpp. *J Bacteriol* 195: 1912–1919. <https://doi.org/10.1128/JB.02134-12>.
42. Hoekstra D, van der Laan JW, de Leij L, Witholt B. 1976. Release of outer membrane fragments from normally growing *Escherichia coli*. *Biochim Biophys Acta* 455:889–899. [https://doi.org/10.1016/0005-2736\(76\)90058-4](https://doi.org/10.1016/0005-2736(76)90058-4).
43. Suzuki H, Nishimura Y, Yasuda S, Nishimura A, Yamada M, Hirota Y. 1978. Murein-lipoprotein of *Escherichia coli*: a protein involved in the stabilization of bacterial cell envelope. *Mol Gen Genet* 167:1–9. <https://doi.org/10.1007/bf00270315>.
44. Schwegheimer C, Kulp A, Kuehn MJ. 2014. Modulation of bacterial outer membrane vesicle production by envelope structure and content. *BMC Microbiol* 14:324. <https://doi.org/10.1186/s12866-014-0324-1>.
45. Xie R, Taylor RJ, Kahne D. 2018. Outer membrane translocon communicates with inner membrane ATPase to stop lipopolysaccharide transport. *J Am Chem Soc* 140:12691–12694. <https://doi.org/10.1021/jacs.8b07656>.
46. Martorana AM, Motta S, Di Silvestre D, Falchi F, Dehò G, Mauri P, Sperandio P, Polissi A. 2014. Dissecting *Escherichia coli* outer membrane biogenesis using differential proteomics. *PLoS One* 9:e100941. <https://doi.org/10.1371/journal.pone.0100941>.
47. Silhavy TJ, Berman ML, Enquist LW (ed). 1984. Experiments with gene fusions. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
48. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol Syst Biol* 2:2006.0008. <https://doi.org/10.1038/msb4100050>.
49. Cherepanov PP, Wackernagel W. 1995. Gene disruption in *Escherichia coli*: TcR and KmR cassettes with the option of FLP-catalyzed excision of the antibiotic-resistance determinant. *Gene* 158:9–14. [https://doi.org/10.1016/0378-1119\(95\)00193-a](https://doi.org/10.1016/0378-1119(95)00193-a).
50. Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP. 1998. A broad-host-range FLP-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked *Pseudomonas aeruginosa* mutants. *Gene* 212:77–86. [https://doi.org/10.1016/s0378-1119\(98\)00130-9](https://doi.org/10.1016/s0378-1119(98)00130-9).
51. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* 97:6640–6645. <https://doi.org/10.1073/pnas.120163297>.
52. Thomason L, Court DL, Bubunenko M, Costantino N, Wilson H, Datta S, Oppenheim A. 2007. Recombineering: genetic engineering in bacteria using homologous recombination. *Curr Protoc Mol Biol* Chapter 1:Unit 1.16–1.16.24. <https://doi.org/10.1002/0471142727.mb0116s78>.